Skip to main content
SpringerLink
Log in

Aclarubicin/cytarabine/granulocyte colony stimulating factors

Cardiac dysfunction: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Qu Q, et al. Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia. Leukemia Research 39: 1353-9, No. 12, Dec 2015. Available from: URL: http://doi.org/10.1016/j.leukres.2015.09.014 - China

    Article  CAS  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aclarubicin/cytarabine/granulocyte colony stimulating factors. Reactions Weekly 1599, 14 (2016). https://doi.org/10.1007/s40278-016-16877-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-016-16877-x

Search

Navigation